13/07/2018 00:24:41

July 16th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

Related content
17 Jul - 
Labaton Sucharow LLP Files Securities Class Action Laws..
16 Jul - 
CLASS ACTION DEADLINE MONDAY for PRTA and FLR: Levi & K..
15 Jul - 
SHAREHOLDER ALERT – PRTA SYMC PPG MFGP FLR ATEN REPH DB..

LOS ANGELES, July 12, 2018 (GLOBE NEWSWIRE) -- National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the July 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena Corporation plc (“Prothena” or the “Company”) (NASDAQ:PRTA) securities between October 15, 2015 and April 20, 2018, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to participate.

Investors suffering losses on their Prothena investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

On October 15, 2015, Prothena announced its late-stage Phase 2b “PRONTO” study and expansion of its Phase 1/2 clinical trial for the antibody NEOD001. On April 23, 2018, Prothena announced it was ending development of NEOD001 after its Phase 2b PRONTO trial failed to reach either its primary or secondary endpoints. On this news, shares of Prothena fell $25.34, or nearly 69%, to close at $11.50 on April 23, 2018, thereby injuring investors.

The complaint filed in this class action alleges that, Defendants during the Class Period violated the federal securities laws by: (1) withholding relevant trial data showing that Prothena’s NEOD001, an antibody designed to treat amyloid light chain amyloidosis (“AL amyloidosis”), was not an effective treatment for AL amyloidosis; (2) making misleading comparisons of NEOD001’s “best response” rates against certain prior studies; and (3) touting that Prothena’s ongoing Phase 1/2 study of NEOD001 provided a strong basis for late-stage Phase 2b and Phase 3 studies of NEOD001, even though the full Phase 1/2 study data demonstrated that NEOD001 was not an effective treatment for AL amyloidosis.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares Prothena during the Class Period you may move the Court no later than July 16, 2018 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay and Murray LLP, Los Angeles

Lesley Portnoy, 310-201-9150 or 888-773-9224

www.glancylaw.com

shareholders@glancylaw.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Second quarter 2018 results - ramping up construction and increasing backlog and pipeline
2
Pittsburgh International Airport Selects World-Renowned Architectural and Engineering Firms with Local Ties to Collaborate on Design of New Terminal
3
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against National Beverage Corp.
4
Sterling National Bank Grows Commercial Banking and Commercial Finance Teams with Key Hires
5
FAURECIA : DOUBLE-DIGIT GROWTH IN SALES AND OPERATING INCOME IN THE FIRST HALF - UPGRADED FULL-YEAR GUIDANCE

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 July 2018 04:59:17
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180712.1 - EUROWEB2 - 2018-07-21 05:59:17 - 2018-07-21 04:59:17 - 1000 - Website: OKAY